ERSTE GROUP BANK logo

ERSTE GROUP BANK (4EBS)

Market Closed
14 Jul, 15:30
XMIL XMIL
111. 70
+0.2
+0.1794%
- Market Cap
- P/E Ratio
7.42% Div Yield
3 Volume
-4.4 Eps
111.5
Previous Close
Add Transaction
Day Range
111.7 116.3
Year Range
54.3 116.3
Want to track 4EBS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

4EBS closed Tuesday higher at €111.7, an increase of 0.1794% from Monday's close, completing a monthly increase of 0% or €111.7. Over the past 12 months, 4EBS stock gained 1.8232%.
4EBS is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.3011%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NYSE (USD).

4EBS Chart

Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Seekingalpha | 1 month ago
Hantavirus cases spark surge in pharma and biotech stocks — here's why

Hantavirus cases spark surge in pharma and biotech stocks — here's why

Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.

Cnbc | 2 months ago
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

ERSTE GROUP BANK (4EBS) FAQ

What is the stock price today?

The current price is €111.70.

On which exchange is it traded?

ERSTE GROUP BANK is listed on XMIL.

What is its stock symbol?

The ticker symbol is 4EBS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 7.42%.

What is its market cap?

As of today, no market cap data is available.

Has ERSTE GROUP BANK ever had a stock split?

No, there has never been a stock split.

ERSTE GROUP BANK Profile

Specialty Retail Industry
Consumer Discretionary Sector
Joseph C. Papa Jr. CEO
XMIL Exchange
US29089Q1058 ISIN
US Country
900 Employees
- Last Dividend
- Last Split
15 Nov 2006 IPO Date

Overview

Emergent BioSolutions Inc. is a life sciences company that specializes in offering preparedness and response solutions against a range of public health threats, including accidental, deliberate, and naturally occurring ones, within the United States. With its foundation dating back to 1998, the company is based in Gaithersburg, Maryland. Emergent BioSolutions Inc. is dedicated to safeguarding public health through its comprehensive portfolio of products designed to combat serious health threats such as opioid overdose, cholera, typhoid fever, anthrax, smallpox, Ebola, and exposure to various chemical and biological warfare agents. In addition to its product offerings, Emergent BioSolutions Inc. extends its expertise through contract development and manufacturing services, emphasizing drug substance and product manufacturing, packaging, technology transfer, and process and analytical development.

Products and Services

  • NARCAN Nasal Spray: Emergency treatment for known or suspected opioid overdose.
  • Vaxchora vaccine: Prevents cholera.
  • Vivotif vaccine: An oral vaccine for the prevention of typhoid fever.
  • Anthrasil: Treats inhalational anthrax.
  • BioThrax: An anthrax vaccine.
  • CYFENDUS: Post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis.
  • Raxibacumab injection: For the treatment and prophylaxis of inhalational anthrax.
  • ACAM2000: A smallpox vaccine.
  • CNJ-016: Addresses complications from smallpox vaccination.
  • TEMBEXA: Treats smallpox disease caused by variola virus in adults and pediatric patients.
  • BAT: Treats symptomatic botulism.
  • Ebanga: Treats Ebola.
  • Reactive Skin Decontamination Lotion Kit: Removes or neutralizes chemical warfare agents from the skin.
  • Trobigard: An atropine sulfate obidoxime chloride auto-injector for chemical warfare agent poisoning.
  • Products under development: Including CGRD-001 for treatment of poisoning by organophosphorus nerve agents, EBS-LASV for Lassa fever prevention, EBS-MARV to prevent Marburg virus disease, and several other vital projects focused on combating infectious diseases and chemical agent exposures.
  • Contract Development and Manufacturing Services: Offers drug substance and product manufacturing, packaging, technology transfer, process, and analytical development services tailored to clients' specific needs.

Contact Information

Address: 400 Professional Drive
Phone: 240 631 3200